|
US6025154A
(en)
|
1995-06-06 |
2000-02-15 |
Human Genome Sciences, Inc. |
Polynucleotides encoding human G-protein chemokine receptor HDGNR10
|
|
US7368111B2
(en)
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
|
WO2000001410A1
(en)
|
1998-07-06 |
2000-01-13 |
Beth Israel Deaconess Medical Center |
Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis
|
|
AU768029B2
(en)
*
|
1999-04-09 |
2003-11-27 |
Hanmi Pharm. Co., Ltd. |
Method for quantifying transforming growth factor-beta1 and method for detecting cancer by using same
|
|
EP1486560A3
(en)
*
|
1999-04-30 |
2005-02-09 |
Cambridge Antibody Technology LTD |
Specific antibodies and antibody fragments for TGFBETA1
|
|
US6492497B1
(en)
*
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
|
US7291714B1
(en)
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
|
US20040001826A1
(en)
|
1999-06-30 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
|
AU7825500A
(en)
*
|
1999-10-07 |
2001-04-23 |
Pharmacia Corporation |
Inhibition enzyme linked immunosorbent assay (iELISA) for the detection and quantification of antibodies in biological samples
|
|
SE9903895D0
(sv)
*
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
|
KR20060088905A
(ko)
|
2000-06-16 |
2006-08-07 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
면역특이적으로 ＢＬｙＳ에 결합하는 항체
|
|
CA2430257A1
(en)
*
|
2000-11-28 |
2002-06-06 |
Amgen, Inc. |
Transforming growth factor-beta-related molecules and uses thereof
|
|
TWI327600B
(en)
|
2000-11-28 |
2010-07-21 |
Medimmune Llc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
|
WO2002064612A2
(en)
*
|
2001-02-09 |
2002-08-22 |
Human Genome Sciences, Inc. |
Human g-protein chemokine receptor (ccr5) hdgnr10
|
|
US7175988B2
(en)
|
2001-02-09 |
2007-02-13 |
Human Genome Sciences, Inc. |
Human G-protein Chemokine Receptor (CCR5) HDGNR10
|
|
KR20030093316A
(ko)
|
2001-04-13 |
2003-12-06 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
혈관 내피 성장 인자 ２
|
|
MXPA03010747A
(es)
|
2001-05-25 |
2004-03-02 |
Human Genome Sciences Inc |
Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
|
|
US7393934B2
(en)
|
2001-12-21 |
2008-07-01 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor (CCR5) HDGNR10
|
|
DE10210427A1
(de)
*
|
2002-03-09 |
2003-10-09 |
Hans Konrad Mueller-Hermelink |
Humaner monoklonaler Antikörper
|
|
JP2005535572A
(ja)
|
2002-04-12 |
2005-11-24 |
メディミューン，インコーポレーテッド |
組換え抗インターロイキン−９抗体
|
|
AU2003274463B2
(en)
|
2002-06-10 |
2009-10-29 |
University Of Rochester |
Gene differentially expressed in breast and bladder cancer and encoded polypeptides
|
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
EP1521776A2
(en)
|
2002-07-04 |
2005-04-13 |
Oncomab Gmbh |
Neoplasm specific antibodies and uses thereof
|
|
SI2301965T1
(sl)
|
2002-10-16 |
2015-07-31 |
Purdue Pharma L.P. |
Protitelesa, ki vežejo celično- povezan CA 125 / O722P in metode uporabe le-teh
|
|
GB0224436D0
(en)
*
|
2002-10-21 |
2002-11-27 |
Univ Cambridge Tech |
Polypetides methods and means
|
|
BR0316880A
(pt)
|
2002-12-23 |
2005-10-25 |
Wyeth Corp |
Anticorpos contra pd-1 e usos dos mesmos
|
|
DE10311248A1
(de)
|
2003-03-14 |
2004-09-30 |
Müller-Hermelink, Hans Konrad, Prof. Dr. |
Humaner monoklonaler Antikörper
|
|
KR101224235B1
(ko)
|
2003-04-11 |
2013-01-25 |
메디뮨 엘엘씨 |
재조합 ｉｌ９ 항체 및 그의 용도
|
|
US20070172446A1
(en)
|
2003-05-16 |
2007-07-26 |
Intermune, Inc. |
Synthetic chemokine receptor ligands and methods of use thereof
|
|
EP1646655A2
(en)
*
|
2003-07-09 |
2006-04-19 |
Eli Lilly And Company |
Tgf-beta1 ligands
|
|
AU2004259727A1
(en)
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Compositions and methods for immunotherapy of cancer and infectious diseases.
|
|
ES2383328T3
(es)
|
2003-07-25 |
2012-06-20 |
Amgen, Inc |
Métodos relacionados con LDCAM y CRTAM
|
|
WO2005014795A2
(en)
|
2003-08-08 |
2005-02-17 |
Genenews Inc. |
Osteoarthritis biomarkers and uses thereof
|
|
EP1531162A1
(en)
|
2003-11-14 |
2005-05-18 |
Heinz Vollmers |
Adenocarcinoma specific antibody SAM-6, and uses thereof
|
|
DE10353175A1
(de)
|
2003-11-14 |
2005-06-16 |
Müller-Hermelink, Hans Konrad, Prof. Dr. |
Humaner monoklonaler Antikörper mit fettsenkender Wirkung
|
|
CA2559809A1
(en)
|
2004-03-12 |
2005-11-10 |
Human Genome Sciences, Inc. |
Antibodies against human g-protein chemokine receptor (ccr5) hdgnr10
|
|
WO2005097832A2
(en)
|
2004-03-31 |
2005-10-20 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
|
JP2008513540A
(ja)
|
2004-09-21 |
2008-05-01 |
メディミューン，インコーポレーテッド |
呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
|
|
JP2008518023A
(ja)
|
2004-10-27 |
2008-05-29 |
メディミューン，インコーポレーテッド |
同族抗原に対する親和性を改変することによる抗体特異性の調節
|
|
EP2520669A3
(en)
|
2005-02-07 |
2013-02-27 |
GeneNews Inc. |
Mild osteoathritis biomarkers and uses thereof
|
|
ES2711213T3
(es)
|
2005-02-08 |
2019-04-30 |
Genzyme Corp |
Anticuerpos de TGFbeta
|
|
KR101289537B1
(ko)
|
2005-02-15 |
2013-07-31 |
듀크 유니버시티 |
항-ｃｄ19 항체 및 종양학에서 이의 용도
|
|
EP1858545A2
(en)
|
2005-03-04 |
2007-11-28 |
Curedm Inc. |
Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
|
|
ATE505489T1
(de)
|
2005-04-22 |
2011-04-15 |
Lilly Co Eli |
Tgf-beta-1-spezifische antikörper
|
|
EP1885755A4
(en)
|
2005-05-05 |
2009-07-29 |
Univ Duke |
CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES
|
|
CA2609667C
(en)
|
2005-05-25 |
2011-02-22 |
Curedm, Inc. |
Human proislet peptide, derivatives and analogs thereof, and methods of using same
|
|
US20070110757A1
(en)
|
2005-06-23 |
2007-05-17 |
Ziping Wei |
Antibody formulations having optimized aggregation and fragmentation profiles
|
|
US8239136B2
(en)
|
2005-10-21 |
2012-08-07 |
Genenews Inc. |
Method, computer system and computer-readable medium for determining a probability of colorectal cancer in a test subject
|
|
US8597646B2
(en)
|
2005-10-25 |
2013-12-03 |
The Johns Hopkins University |
Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders
|
|
EP2540741A1
(en)
|
2006-03-06 |
2013-01-02 |
Aeres Biomedical Limited |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
US8454952B2
(en)
|
2006-03-13 |
2013-06-04 |
The Johns Hopkins University |
Augmentation of endothelial thromboresistance
|
|
US9056906B2
(en)
|
2006-06-14 |
2015-06-16 |
Macrogenics, Inc. |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
|
WO2008027338A2
(en)
|
2006-08-28 |
2008-03-06 |
Kyowa Hakko Kirin Co., Limited |
Antagonistic human light-specific human monoclonal antibodies
|
|
ES2647472T3
(es)
|
2006-10-03 |
2017-12-21 |
Genzyme Corporation |
Anticuerpos contra TGF-BETA para uso en el tratamiento de lactantes con riesgo de desarrollar displasia broncopulmonar
|
|
WO2008064306A2
(en)
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
|
EP2687232A1
(en)
|
2006-12-06 |
2014-01-22 |
MedImmune, LLC |
Methods of treating systemic lupus erythematosus
|
|
WO2008121615A2
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Inc. |
Antibody formulation
|
|
EP2703011A3
(en)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
WO2008143878A1
(en)
|
2007-05-14 |
2008-11-27 |
Medimmune, Llc |
Methods of reducing eosinophil levels
|
|
US8816047B2
(en)
|
2007-08-30 |
2014-08-26 |
Cure DM Group Holdings, LLC |
Compositions and methods of using proislet peptides and analogs thereof
|
|
HUE025787T2
(en)
|
2007-11-05 |
2016-05-30 |
Medimmune Llc |
Method for treating scleroderma
|
|
EP2225275A4
(en)
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
PROTEIN FORMULATION
|
|
ES2613963T3
(es)
|
2008-01-18 |
2017-05-29 |
Medimmune, Llc |
Anticuerpos manipulados con cisteína para conjugación específica de sitio
|
|
PL2250279T3
(pl)
|
2008-02-08 |
2016-11-30 |
|
Przeciwciała anty-ifnar1 o zmniejszonym powinowactwie do liganda fc
|
|
CN103408663B
(zh)
|
2008-10-31 |
2016-01-27 |
东丽株式会社 |
抗人cxcl1单克隆抗体或其片段
|
|
CN102438652B
(zh)
|
2008-11-12 |
2014-08-13 |
米迪缪尼有限公司 |
抗体制剂
|
|
EP2387584A1
(en)
|
2009-01-14 |
2011-11-23 |
IQ Therapeutics BV |
Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
|
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
|
EP2711018A1
(en)
|
2009-06-22 |
2014-03-26 |
MedImmune, LLC |
Engineered Fc regions for site-specific conjugation
|
|
DK2464664T3
(da)
|
2009-08-13 |
2016-01-18 |
Crucell Holland Bv |
Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
|
|
EP2496243A2
(en)
|
2009-11-04 |
2012-09-12 |
Erasmus University Medical Center Rotterdam |
Novel compounds for modulating neovascularisation and methods of treatment using these compounds
|
|
PL3117709T3
(pl)
|
2010-03-12 |
2019-01-31 |
Genzyme Corporation |
Terapia skojarzona do leczenia raka piersi
|
|
BR112012031638B1
(pt)
|
2010-07-09 |
2021-01-12 |
Janssen Vaccines & Prevention B.V. |
anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado
|
|
US8956868B2
(en)
|
2010-12-27 |
2015-02-17 |
Lsip, Llc |
Induced pluripotent stem cells produced with a connexin inhibitor and a TGF-β signaling inhibitor
|
|
DK2668210T3
(da)
|
2011-01-26 |
2020-08-24 |
Celldex Therapeutics Inc |
Anti-kit antistoffer og anvendelser deraf
|
|
US20140308275A1
(en)
|
2011-07-27 |
2014-10-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale |
Methods for diagnosing and treating myhre syndrome
|
|
IN2014DN03049A
(OSRAM)
|
2011-10-26 |
2015-05-15 |
Seattle Childrens Res Inst |
|
|
US9782452B2
(en)
|
2011-11-22 |
2017-10-10 |
Cornell University |
Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
|
|
CA3111357A1
(en)
|
2011-12-23 |
2013-06-27 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
JP6218229B2
(ja)
|
2011-12-28 |
2017-10-25 |
京都府公立大学法人 |
角膜内皮細胞の培養正常化
|
|
US9365641B2
(en)
|
2012-10-01 |
2016-06-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
ES2885423T3
(es)
|
2013-02-07 |
2021-12-13 |
Massachusetts Gen Hospital |
Procedimientos para la expansión o el empobrecimiento de células T reguladoras
|
|
WO2014129895A1
(en)
|
2013-02-19 |
2014-08-28 |
Stichting Vu-Vumc |
Means and method for increasing the sensitivity of cancers for radiotherapy
|
|
KR102258457B1
(ko)
|
2013-03-11 |
2021-05-31 |
젠자임 코포레이션 |
조작된 항-tgf-베타 항체 및 항원-결합 단편
|
|
DK3702443T3
(da)
|
2013-03-14 |
2022-04-04 |
Brigham & Womens Hospital Inc |
Sammensætninger og fremgangsmåder til opformering og dyrkning af epiteliale stamceller
|
|
NZ714765A
(en)
|
2013-06-06 |
2021-12-24 |
Pf Medicament |
Anti-c10orf54 antibodies and uses thereof
|
|
WO2014200349A1
(en)
|
2013-06-13 |
2014-12-18 |
Fast Forward Pharmaceutical B.V. |
Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
|
|
CA2922478C
(en)
|
2013-08-26 |
2020-09-29 |
MabVax Therapeutics, Inc. |
Nucleic acids encoding human antibodies to sialyl-lewisa
|
|
BR112016007037B1
(pt)
|
2013-10-01 |
2023-12-26 |
National Cancer Center |
Método para detectar câncer pancreático
|
|
ES2847755T3
(es)
|
2013-10-31 |
2021-08-03 |
Kyoto Prefectural Public Univ Corp |
Fármaco terapéutico que comprende un inhibidor de la señal de TGF-beta para enfermedades relacionadas con la muerte celular del retículo endoplásmico en el endotelio corneal
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
SG10201912986PA
(en)
|
2014-05-28 |
2020-02-27 |
Agenus Inc |
Anti-gitr antibodies and methods of use thereof
|
|
DK3154583T3
(da)
|
2014-06-04 |
2021-03-22 |
Biontech Res And Development Inc |
Humane monoklonale antistoffer mod gangliosid gd2
|
|
KR102493376B1
(ko)
|
2014-09-03 |
2023-01-27 |
더 브리검 앤드 우먼즈 하스피털, 인크. |
청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법
|
|
CN106715473B
(zh)
|
2014-10-01 |
2021-11-23 |
免疫医疗有限公司 |
替格瑞洛的抗体及其使用方法
|
|
TN2017000246A1
(en)
|
2014-12-11 |
2018-10-19 |
Pf Medicament |
Anti-c10orf54 antibodies and uses thereof
|
|
JP7211703B2
(ja)
|
2014-12-22 |
2023-01-24 |
ザ ロックフェラー ユニバーシティー |
抗ｍｅｒｔｋアゴニスト抗体及びその使用
|
|
US11231423B2
(en)
|
2015-01-26 |
2022-01-25 |
Toray Industries, Inc. |
Method and kit for the detection of biliary tract cancer
|
|
US11162956B2
(en)
|
2015-03-02 |
2021-11-02 |
Toray Industries, Inc. |
Method and kit for the detection of pancreatic dysfunction
|
|
CN114504652A
(zh)
|
2015-03-03 |
2022-05-17 |
科马布有限公司 |
抗体、用途和方法
|
|
CN115109158A
(zh)
|
2015-05-07 |
2022-09-27 |
阿吉纳斯公司 |
抗ox40抗体及其使用方法
|
|
CN107849142B
(zh)
|
2015-05-15 |
2022-04-26 |
综合医院公司 |
拮抗性抗肿瘤坏死因子受体超家族抗体
|
|
US10882903B2
(en)
|
2015-05-18 |
2021-01-05 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Methods and compositions for treating an alphavirus infection
|
|
US10144779B2
(en)
|
2015-05-29 |
2018-12-04 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
|
US20190135929A1
(en)
|
2015-08-28 |
2019-05-09 |
The General Hospital Corporation |
Agonistic anti-tumor necrosis factor receptor 2 antibodies
|
|
KR20220131277A
(ko)
|
2015-09-01 |
2022-09-27 |
아게누스 인코포레이티드 |
항-pd-1 항체 및 이를 이용하는 방법
|
|
JP2019506153A
(ja)
|
2016-01-08 |
2019-03-07 |
マサチューセッツ インスティテュート オブ テクノロジー |
分化した腸内分泌細胞およびインスリン産生細胞の作製
|
|
US11180546B2
(en)
*
|
2016-02-17 |
2021-11-23 |
Novartis Ag |
TGFbeta 2 antibodies
|
|
US10213511B2
(en)
|
2016-03-02 |
2019-02-26 |
Frequency Therapeutics, Inc. |
Thermoreversible compositions for administration of therapeutic agents
|
|
US11260130B2
(en)
|
2016-03-02 |
2022-03-01 |
Frequency Therapeutics, Inc. |
Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
|
|
US10201540B2
(en)
|
2016-03-02 |
2019-02-12 |
Frequency Therapeutics, Inc. |
Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
|
|
BR112018068340A2
(pt)
|
2016-03-11 |
2019-01-15 |
Scholar Rock Inc |
imunoglobulinas de ligação ao tgfss1 e usos destas
|
|
EP3455262A4
(en)
|
2016-05-13 |
2020-04-08 |
The General Hospital Corporation |
ANTAGONIST ANTIBODIES OF THE NECROSIS FACTOR RECEPTOR SUPERFAMILY AGAINST TUMORS
|
|
AU2017268234A1
(en)
|
2016-05-17 |
2018-12-13 |
Genentech, Inc. |
Stromal gene signatures for diagnosis and use in immunotherapy
|
|
KR20230091191A
(ko)
|
2016-05-27 |
2023-06-22 |
아게누스 인코포레이티드 |
항-tim-3 항체 및 이의 사용 방법
|
|
MA45602A
(fr)
|
2016-07-08 |
2019-05-15 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs méthodes d'utilisation
|
|
BR112019007369A2
(pt)
|
2016-10-11 |
2019-07-16 |
Agenus Inc |
anticorpos anti-lag-3 e métodos de uso dos mesmos
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
US11332521B2
(en)
|
2016-11-07 |
2022-05-17 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
|
CA3046082A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
MA50949B1
(fr)
|
2016-12-07 |
2023-12-29 |
Memorial Sloan Kettering Cancer Center |
Anticorps anti-ctla-4 et leurs procédés d'utilisation
|
|
SG10201910821XA
(en)
|
2016-12-30 |
2020-01-30 |
Frequency Therapeutics Inc |
1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
|
|
TWI787230B
(zh)
|
2017-01-20 |
2022-12-21 |
法商賽諾菲公司 |
抗ＴＧＦ-β抗體及其用途
|
|
TW202421659A
(zh)
|
2017-01-20 |
2024-06-01 |
美商健臻公司 |
骨靶向抗體
|
|
KR102629972B1
(ko)
|
2017-04-13 |
2024-01-29 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
|
CN110506056A
(zh)
|
2017-04-21 |
2019-11-26 |
斯塔滕生物技术有限公司 |
抗apoc3抗体和其使用方法
|
|
EP3618863B1
(en)
|
2017-05-01 |
2023-07-26 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
WO2019003165A1
(en)
|
2017-06-27 |
2019-01-03 |
Neuracle Science Co., Ltd. |
ANTI-FAM19A5 ANTIBODIES AND USES THEREOF
|
|
CA3070774A1
(en)
|
2017-08-25 |
2019-02-28 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
|
JP7256796B2
(ja)
|
2017-10-13 |
2023-04-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体
|
|
MX2020004512A
(es)
|
2017-10-31 |
2020-08-13 |
|
Anticuerpos anti apolipoproteina c-iii (anti-apoc3) y metodos de uso de los mismos.
|
|
CA3077664A1
(en)
|
2017-11-06 |
2019-05-09 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
JP7165193B2
(ja)
|
2017-11-27 |
2022-11-02 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
ヒト組織因子を標的とするヒト化抗体
|
|
EP3755720A1
(en)
|
2018-02-21 |
2020-12-30 |
Five Prime Therapeutics, Inc. |
B7-h4 antibody formulations
|
|
AU2019228600A1
(en)
|
2018-03-02 |
2020-09-24 |
Five Prime Therapeutics, Inc. |
B7-H4 antibodies and methods of use thereof
|
|
JP7530638B2
(ja)
|
2018-05-10 |
2024-08-08 |
ニューラクル サイエンス カンパニー リミテッド |
配列類似性１９、メンバーａ５抗体を有する抗ファミリー及びその使用方法
|
|
US12006357B2
(en)
|
2018-06-26 |
2024-06-11 |
Mor Research Applications Ltd. |
Transthyretin antibodies and uses thereof
|
|
BR112021000934A2
(pt)
|
2018-07-20 |
2021-04-27 |
Pierre Fabre Medicament |
receptor para vista
|
|
EP3837352A1
(en)
|
2018-08-17 |
2021-06-23 |
Frequency Therapeutics, Inc. |
Compositions and methods for generating hair cells by upregulating jag-1
|
|
WO2020037215A1
(en)
|
2018-08-17 |
2020-02-20 |
Icahn School Of Medicine At Mount Sinai |
Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
|
|
US11617745B2
(en)
|
2018-08-17 |
2023-04-04 |
Frequency Therapeutics, Inc. |
Compositions and methods for generating hair cells by downregulating FOXO
|
|
CN112839957A
(zh)
|
2018-09-28 |
2021-05-25 |
协和麒麟株式会社 |
Il-36抗体及其用途
|
|
CN112969503A
(zh)
|
2018-10-03 |
2021-06-15 |
斯塔滕生物技术有限公司 |
对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
|
|
WO2020128927A1
(en)
|
2018-12-20 |
2020-06-25 |
Kyowa Kirin Co., Ltd. |
Fn14 antibodies and uses thereof
|
|
CN117964756A
(zh)
|
2019-01-02 |
2024-05-03 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5的抗体及其使用方法
|
|
MX2021010003A
(es)
|
2019-02-26 |
2021-12-10 |
Inspirna Inc |
Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
|
|
CN113874392B
(zh)
|
2019-03-28 |
2025-10-21 |
丹尼斯科美国公司 |
工程化抗体
|
|
JP2022527972A
(ja)
|
2019-04-02 |
2022-06-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
前悪性病変を有する患者において癌を予測及び予防する方法
|
|
WO2021030488A1
(en)
|
2019-08-12 |
2021-02-18 |
Bienvenue David Leonard |
4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
|
|
US11680098B2
(en)
|
2019-08-30 |
2023-06-20 |
Agenus Inc. |
Antibodies that specifically bind human CD96
|
|
EP4025606A1
(en)
|
2019-09-04 |
2022-07-13 |
Y-Biologics Inc. |
Anti-vsig4 antibody or antigen binding fragment and uses thereof
|
|
CN112852738B
(zh)
*
|
2019-11-27 |
2023-02-28 |
四川省肿瘤医院 |
一种前列腺癌细胞膜片的制备方法
|
|
MX2022010021A
(es)
|
2020-02-18 |
2022-11-09 |
Alector Llc |
Anticuerpos de pilra y sus metodos de uso.
|
|
EP4114445A1
(en)
|
2020-03-06 |
2023-01-11 |
Ona Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
|
ES2973425T3
(es)
|
2020-03-26 |
2024-06-20 |
Univ Vanderbilt |
Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del síndrome respiratorio agudo grave (sars-cov-2)
|
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
|
JP2023528235A
(ja)
|
2020-05-17 |
2023-07-04 |
アストラゼネカ・ユーケイ・リミテッド |
ＳＡＲＳ－ＣｏＶ－２抗体、並びにこれを選択及び使用する方法
|
|
AU2021313348A1
(en)
|
2020-07-20 |
2023-03-09 |
Astrazeneca Uk Limited |
SARS-CoV-2 proteins, anti-SARS-CoV-2 antibodies, and methods of using the same
|
|
PE20231187A1
(es)
|
2020-08-18 |
2023-08-15 |
Cephalon Llc |
Anticuerpos anti-par-2 y metodos de uso de los mismos
|
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
|
US20240301086A1
(en)
|
2020-12-01 |
2024-09-12 |
Aptevo Research And Development Llc |
Tumor-associated antigens and cd3-binding proteins, related compositions, and methods
|
|
WO2022184853A1
(en)
|
2021-03-03 |
2022-09-09 |
Pierre Fabre Medicament |
Anti-vsig4 antibody or antigen binding fragment and uses thereof
|
|
JPWO2022202826A1
(OSRAM)
|
2021-03-24 |
2022-09-29 |
|
|
|
EP4348263A1
(en)
|
2021-05-28 |
2024-04-10 |
Alexion Pharmaceuticals, Inc. |
Methods for detecting cm-tma biomarkers
|
|
JP2024522213A
(ja)
|
2021-06-14 |
2024-06-11 |
アルジェニクス ビーブイ |
抗ｉｌ－９抗体及びその使用方法
|
|
JP2024529502A
(ja)
|
2021-07-30 |
2024-08-06 |
オーエヌエー セラピューティクス エセ．エレ． |
抗ｃｄ３６抗体及び癌を治療するためのそれらの使用
|
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
|
TW202342510A
(zh)
|
2022-02-18 |
2023-11-01 |
英商Ｒｑ生物科技有限公司 |
抗體
|
|
WO2023192436A1
(en)
|
2022-03-31 |
2023-10-05 |
Alexion Pharmaceuticals, Inc. |
Singleplex or multiplexed assay for complement markers in fresh biological samples
|
|
CR20240528A
(es)
|
2022-04-29 |
2025-04-04 |
Astrazeneca Uk Ltd |
Anticuerpos contra el sars-cov-2 y métodos para utilizarlos
|
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
|
JP2025525530A
(ja)
|
2022-07-15 |
2025-08-05 |
ヤンセン バイオテツク，インコーポレーテツド |
抗原結合可変領域の改善された生物工学による対合のための材料及び方法
|
|
EP4554619A1
(en)
|
2022-07-15 |
2025-05-21 |
Danisco US Inc. |
Methods for producing monoclonal antibodies
|
|
CA3266977A1
(en)
|
2022-09-06 |
2024-03-14 |
Alexion Pharmaceuticals, Inc. |
DIAGNOSTIC AND PROGNOSIS BIOMARKER PROFILES IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)
|
|
EP4599088A1
(en)
|
2022-10-05 |
2025-08-13 |
Genentech, Inc. |
Methods and compositions for classifying and treating lung cancer
|
|
WO2024077095A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating bladder cancer
|
|
AU2024240129A1
(en)
|
2023-03-17 |
2025-10-09 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024194685A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024243578A1
(en)
|
2023-05-25 |
2024-11-28 |
Dispatch Biotherapeutics, Inc. |
Synthetic cancer antigens as targets for treating cancers
|
|
WO2025072888A2
(en)
|
2023-09-28 |
2025-04-03 |
Novavax, Inc. |
Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
|
|
WO2025133707A1
(en)
|
2023-12-19 |
2025-06-26 |
Vectory Therapeutics B.V. |
Anti-tdp-43 antibodies and uses thereof
|
|
WO2025171383A2
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens and related methods and uses
|
|
WO2025171388A1
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens with modified domains and related methods and uses
|
|
US20250361297A1
(en)
|
2024-03-12 |
2025-11-27 |
Adaptam Therapeutics, S.L. |
Anti- siglec-15 binding molecules and methods of use
|